Risk factor
Very high price volatility
Profitability factor
Very strong margins and returns
About
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology, bioanalysis, sequencing (NGS), and 2D and 3D imaging. The company was incorporated in 2008 and is based in Horsholm, Denmark.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITD
Target Price
The average target price of GUBRA.CO is 462 and suggests 30% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell